ID
19933
Beschreibung
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. Documentation process: This form is to be obtained in Baseline Week 0, week 12, week 36, week 60, week 72, week 84, week 96, week 108 and week 120.
Stichworte
Versionen (3)
- 30.01.17 30.01.17 -
- 31.01.17 31.01.17 -
- 31.01.17 31.01.17 -
Hochgeladen am
31. Januar 2017
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Antibody and PK Pre-Dose CRFs Multiple Sclerosis Tysabri NCT00027300
Antibody and PK Pre-Dose CRFs Multiple Sclerosis Tysabri NCT00027300
Ähnliche Modelle
Antibody and PK Pre-Dose CRFs Multiple Sclerosis Tysabri NCT00027300
C1516698 (UMLS CUI [1,2])
C0031327 (UMLS CUI [1,2])